At issue: Predicting drug-free treatment response in acute psychosis from the Soteria project

Schizophrenia Bulletin

Volumn 28, Issue 4, 2002, Pages 559-575

  Bola, John R ^a   Mosher, Loren R ^b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Soteria Associates   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic; First episode; Neuroleptic; Psychosis; Schizophrenia; Subgroup; Subtype

Indexed keywords

NEUROLEPTIC AGENT;

ACUTE PSYCHOSIS; ADULT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL HEALTH; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; REMISSION; REVIEW; SOCIAL ASPECT; TREATMENT OUTCOME;

EID: 0038185229     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006964     Document Type: Review

References (75)

1. American Psychiatric Association. DSM-II: Diagnostic and Statistical Manual of Mental Disorders. 2nd ed. Washington, DC: APA, 1968.
2. American Psychiatric Association. DSM-III: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: APA, 1980.
3. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA, 1994.
4. Beaman, A.L. An empirical comparison of meta-analytic and traditional reviews. Personality and Social Psychology Bulletin, 17(3):252-257, 1991.
5. Bleuler, E. (1908) The prognosis of dementia praecox: The group of schizophrenias. In: Cutting, J., and Sheperd, M., eds. The Clinical Roots of the Schizophrenia Concept: Translations of Seminal European Contributions on Schizophrenia. New York, NY: Cambride University Press, 1987 (1908). pp. 59-74.
6. Bleuler, M.E. The long-term course of schizophrenic psychosis. In: Wynne, L.C.; Cromwell, R.L.; and Matthysse, S., eds. The Nature of Schizophrenia: New Approaches to Research and Treatment. New York, NY: John Wiley and Sons, 1978. pp. 631-636.
7. Bola, J.R. Evaluation of treatment in early episode acute psychosis: A secondary analysis of the Soteria study. School of Social Welfare. Berkeley, CA: University of California, 1998.
8. Bola, J.R., and Mosher, L.R. The treatment of acute psychosis without neuroleptics: Two-year outcomes from the Soteria project. Journal of Nervous and Mental Disease, in press.
9. Borenstein, M., and Cohen, J. Statistical Power Analysis: A Computer Program. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
10. Buchanan, R.W., and Carpenter, W.T. Targeted maintenance treatment in schizophrenia: Issues and recommendations. CNS Drugs, 5(4):240-245, 1996.
11. Buckley, P. Identifying schizophrenic patients who should not receive medication. Schizophrenia Bulletin, 8(3):429-432, 1982.
12. Carpenter, W.T. The risk of medication-free research. Schizophrenia Bulletin, 23(1):11-18, 1997.
13. Carpenter, W.T. Medication-free research and patient safety. Schizophrenia Bulletin, 24(1):35-36, 1998.
14. Carpenter, W.T., and Heinrichs, D.W. Treatment-relevant subtypes of schizophrenia. Journal of Nervous and Mental Disease, 169(2):113-119, 1981.
15. Carpenter, W.T.; McGlashan, T.H.; and Strauss, J.S. The treatment of acute schizophrenia without drugs: An investigation of some current assumptions. American Journal of Psychiatry, 134(1):14-20, 1977.
16. Chouinard, G.; Jones, B.D.; and Annable, L. Neurolepticinduced supersensitivity psychosis. American Journal of Psychiatry, 135(11):1409-1410, 1978.
17. Ciompi, L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin, 6(4):606-618, 1980a.
18. Ciompi, L. The natural history of schizophrenia in the long term. British Journal of Psychiatry, 136:413-420, 1980b.
19. Cole, J.O.; Goldberg, S.C.; and Davis, J.M. Drugs in the treatment of psychosis: Controlled studies. In: Solomon, P., ed. Psychiatric Drugs: Proceedings of a Research Conference Held in Boston. New York, NY: Grune and Stratton, 1966. pp. 153-180.
20. Cole, J.O.; Klerman, G.L.; Goldberg, S.C.; and National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry, 10:246-261, 1964.
21. Davis, J.M.; Barter, J.T.; and Kane, J.M. Antipsychotic drugs. In: Kaplan, H.I., and Sadock, B.J., eds. Comprehensive Textbook of Psychiatry. Baltimore, MD: Williams and Wilkins, 1989. pp. 1591-1626.
22. Davis, J.M.; Schaffer, C.B.; Killian, G.A.; Kinard, C.; and Chen, C. Important issues in the drug treatment of schizophrenia. Schizophrenia Bulletin, 6(1):70-87, 1980.
23. Dickersin, K., and Min, Y.I. Publication bias: The problem that won't go away. Annals of the New York Academy of Sciences, 703:135-146, 1993.
24. Dixon, L.B.; Lehman, A.F.; and Levine, J. Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin, 21(4):567-577, 1995.
25. Efron, B. The Jacknife, the Bootstrap, and Other Resampling Plans. Philadelphia, PA: Society for Industrial and Applied Mathematics, 1982.
26. Eitinger, L.; Laane, C.; and Langfeldt, G. Prognostic value of clinical picture and therapeutic value of physical treatment in schizophrenia and schizophreniform states. Acta Psychiatrica et Neurologica, 33:33-53, 1958.
27. Evans, J.R.; Rodnick, E.H.; Goldstein, M.J.; and Judd, L.L. Premorbid adjustment, phenothiazine treatment, and remission in acute schizophrenics. Archives of General Psychiatry, 27:486-490, 1972.
28. Geddes, J.; Freemantle, N.; Harrison, P.; and Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal, 321:1371-1376, 2000.
29. Gelenberg, A.J. Acute and chronic adverse effects of neuroleptics. In: Pollack, M.H.; Otto, M.W.; and Rosenbaum, J.E., eds. Challenges in Clinical Practice: Pharmacological and Psychosocial Strategies. New York, NY: Guilford Press, 1996. pp. 481-489.
30. Goldberg, S.C.; Klerman, G.L.; and Cole, J.O. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry, 111:120-133, 1965.
31. Goldstein, M.J. Premorbid adjustment, paranoid status, and patterns of response to phenothiazine in acute schizophrenia. Schizophrenia Bulletin, 1(3):24-37, 1970.
32. Greene, W. Econometric Analysis. Upper Saddle River, NJ: Prentice Hall, 1997.
33. Greene, W.H. LIMDEP: Version 7.0 Users Manual. Plainview, NY: Econometric Software, 1995.
34. Harding, C.M.; Brooks, G.W.; Ashikaga, T.; Strauss, J.S.; and Breier, A. The Vermont longitudinal study of persons with severe mental illness: II. Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. American Journal of Psychiatry, 144(6):727-735, 1987.
35. Heckman, J.J. Sample selection bias as a specification error. Econometrica, 47(1):153-161, 1979.
36. Hollingshead, A.B. Two Factor Index of Social Position. New Haven, CT: August Hollingshead, 1957.
37. Huber, G.; Gross, G.; Schuttler, R.; and Linz, M. Longitudinal studies of schizophrenic patients. Schizophrenia Bulletin, 6(4):592-605, 1980.
38. Johnstone, E.C.; Owens, D.G.; Crow, T.J.; and Davis, J.M. Does a four-week delay in the introduction of medication alter the course of functional psychosis? Journal of Psychopharmacology, 13(3):238-244, 1999.
39. Judd, L.L.; Goldstein, M.J.; Rodnick, E.H.; and Jackson, N.L. Phenothiazine effects in good premorbid schizophrenics divided into paranoid-nonparanoid status. Archives of General Psychiatry, 29:207-211, 1973.
40. Kirch, D.G.; Keith, S.J.; and Matthews, S.M. Research on first episode psychosis: Report on a National Institute of Mental Health workshop. Schizophrenia Bulletin, 18(2):179-184, 1992.
41. Langfeldt, G. The Schizophreniform States: A Katamnestic Study Based on Individual Reexaminations. Copenhagen, Denmark: Einar Munksgaard, 1939.
42. Langfeldt, G. Schizophrenia: Diagnosis and prognosis. Behavioral Science, 14:173-182, 1969.
43. Lehtinen, V.; Aaltonen, J.; Koffert, T.; Rakkolainen, V.; and Syvalahti, E. Two-year outcome in first-episode psychosis treated according to an integrated model: Is immediate neuroleptisation always needed? European Psychiatry, 15(5):312-320, 2000.
44. Liberman, R.P.; Falloon, I.R.; and Wallace, C.J. Drug-psychosocial interactions in the treatment of schizophrenia. In: Mirabi, M., ed. The Chronically Mentally III: Research and Services. New York, NY: Spectrum Publications, 1984. pp. 175-212.
45. Maddala, G.S. Econometrics. New York, NY: McGrawHill Publishing Company, 1977.
46. Marder, S.R.; van Kammen, D.P.; Docherty, J.P.; Rayner, J.; and Bunney, W.E. Predicting drug-free improvement in schizophrenic psychosis. Archives of General Psychiatry, 36:1080-1085, 1979.
47. Matthews, S.M.; Roper, M.T.; Mosher, L.R.; and Menn, A.Z. A non-neuroleptic treatment for schizophrenia: Analysis of the two-year postdischarge risk of relapse. Schizophrenia Bulletin, 5(2):322-333, 1979.
48. May, P.R. Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods. New York, NY: Science House, 1968.
49. May, P.R.; Tuma, A.H.; Dixon, W.J.; Yale, C.; Theile, D.A.; and Kraude, W.H. Schizophrenia: A follow-up study of the results of five forms of treatment. Archives of General Psychiatry, 38:776-784, 1981.
50. Mechanic, D. Toward the year 2000 in U.S. mental health policy making and administration. In: Rochefort, D.A., ed. Handbook on Mental Health Policy in the United States. New York, NY: Greenwood Press, 1989. pp. 477-503.
51. Mosher, L.R. A research design for evaluating psychosocial treatment for schizophrenia. Hospital and Community Psychiatry, 23(8):17-22, 1972.
52. Mosher, L.R., and Meltzer, H.Y. Drugs and psychosocial treatment: Editor's introduction. Schizophrenia Bulletin, 6(1):8-9, 1980.
53. Mosher, L.R., and Menn, A.Z. Community residential treatment for schizophrenia: Two-year follow-up. Hospital and Community Psychiatry, 29(11):715-723, 1978.
54. Mosher, L.R.; Pollin, W.; and Stabenau, R. Identical twins discordant for schizophrenia: Neurologic findings. Archives of General Psychiatry, 24(5):422-430, 1971.
55. Mosher, L.R.; Vallone, R.; and Menn, A. The treatment of acute psychosis without neuroleptics: Six-week psychopathology outcome data from the Soteria project. International Journal of Social Psychiatry, 41(3):157-173, 1995.
56. National Association of Psychiatric Survivors. NAPS/NEWS. Sioux Falls, ND: National Association of Psychiatric Survivors, 1991.
57. National Association of Rights Protection and Advocacy. The Rights Tenet. Minneapolis, MN: Mental Health Association of Minnesota, 1991.
58. National Institute of Mental Health. Caring for People With Severe Mental Disorders: A National Plan of Research to Improve Services. Washington, DC: U.S. Government Printing Office, 1991.
59. Neter, J.; Kutner, M.H.; Nachtsheim, C.J.; and Wasserman, W. Applied Linear Statistical Models. Chicago, IL: Irwin, 1996.
60. Perkins, D.O., and Lieberman, J.A. Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. American Journal of Psychiatry, 155(2):272-276, 1998.
61. Rappaport, M.; Hopkins, H.K.; Hall, K.; Belleza, T.; and Silverman, J. Are there schizophenics for whom drugs may be unnecessary or contraindicated? International Pharmacopsychiatry, 13(2):100-111, 1978.
62. Rodnick, E.H., and Goldstein, M.J. Premorbid adjustment and recovery of mothering function in acute schizophrenic women. Journal of Abnormal Psychology, 83:623-628, 1974.
63. Schooler, N.R. Advances in maintenance treatment. Psychiatric Annals, 26(8):519-522, 1996.
64. Schooler, N.R.; Goldberg, S.C.; Boothe, H.; and Cole, J.O. One year after discharge: Community adjustment of schizophrenic patients. American Journal of Psychiatry, 123(8):986-995, 1967.
65. Sokis, D.A. A brief follow-up rating. Comprehensive Psychiatry, 11(5):445-459, 1970.
66. Strauss, J.S., and Bellak, L. Epilogue: Subtypes of the schizophrenic syndrome - their current status. Schizophrenia Bulletin, 5(3):507-508, 1979.
67. Strauss, J.S., and Carpenter, W.T. The prognosis of schizophrenia: Rationale for a multidimensional concept. Schizophrenia Bulletin, 4(1):56-67, 1978.
68. Thornley, B.; Adams, C.E.; and Awad, G. Chlorpromazine versus placebo for those with schizophrenia. Cochrane Database of Systematic Reviews, 4, 2000.
69. Vaillant, G.E. The prediction of recovery in schizophrenia. Journal of Nervous and Mental Disease, 135:534-543, 1962.
70. Vaillant, G.E. Prospective prediction of schizophrenic remission. Archives of General Psychiatry, 11:509-518, 1964.
71. Venables, P.H., and O'Connor, N. A short scale for rating paranoid schizophrenia. Journal of Mental Science, 105(July):815-818, 1959.
72. Voruganti, L.; Cortese, L.; Oyewumi, L.; Cernovsky, Z.; Zirul, S.; and Awad, A. Comparative evaluation of conventional and novel antipsychotics with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophrenia Research, 43(2-3):135-145, 2000.
73. Warner, R. Recovery From Schizophrenia: Psychiatry and Political Economy. London, U.K.: Routledge and Kegan Paul, 1985.
74. Wyatt, R.J. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17(2):325-351, 1991.
75. Young, M.A., and Meltzer, H.Y. The relationship of demographic, clinical, and outcome variables to neuroleptic treatment requirements. Schizophrenia Bulletin, 6(1):88-101, 1980.